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Abstract 22 
As malnourishment in humans with chronic kidney disease (CKD) is associated with increased 23 
morbidity and mortality, oral supplementation with amino acids is proposed. In dogs, malnutrition 24 
may be associated with CKD and increases the rate of renal-related complication and mortality. 25 
Aim of this retrospective study was to verify the impact of amino acid supplementation on body 26 
weight, serum albumin, creatinine and urea concentrations, and urine protein-to-creatinine (UPC) 27 
ratio in proteinuric CKD dogs. Forty-six client-owned azotemic dogs with spontaneous proteinuric 28 
CKD already on a renal diet and in therapy with enalapril were included. After approximately one 29 
month of treatment (baseline), 29 dogs received oral amino acid supplementation daily (group A), 30 
whereas 17 dogs did not (group B). The amount of amino acids was calculated as follows: body 31 
weight (kg) × [UPC ratio] × 20 = X , where X are the milligrams of amino acids to be administered 32 
daily. Body weight, serum albumin, creatinine and urea concentrations, as well as the UPC ratio 33 
were determined at baseline and after 4-8 weeks in both groups. Compared to baseline, body weight 34 
increased (P<0.01) at follow-up in group A, while it did not change in group B. Serum albumin 35 
concentration increased (P<0.05) in group A and it did not change in group B. Serum creatinine 36 
concentration did not vary in both groups; urea concentration (P<0.05) and UPC ratio (P<0.01) 37 
decreased in group B, but not in group A. Although supplementation with amino acids increased 38 
body weight and serum albumin concentration in dogs, maintaining stable serum creatinine 39 
concentration, it might have prevented a decrease of proteinuria and of urea. Amino acid 40 
supplementation may be considered in the treatment of proteinuric dogs, if hypoalbuminemia is 41 
severe and antiproteinuric therapy is not effective. 42 
 43 
Abbreviations: amino acids, AA; angiotensin converting enzyme inhibitors, ACEI; borderline 44 
proteinuria, BP; body weight, BW; chronic kidney disease, CKD; dry matter, DM; International 45 
Renal Interest Society, IRIS; non-proteinuric, NP; proteinuric, P; urine protein-to-creatinine, UPC. 46 
 47 
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Introduction 48 
In dogs, proteinuria is often associated with chronic kidney disease (CKD) and studies in this 49 
species led to hypothesize that it may promote the progression of renal damage, as it happens in 50 
humans (1-8). In endemic areas for vector-borne diseases, such as leishmaniosis, the prevalence of 51 
dogs with proteinuria, azotemia, or both, has been reported to be up to 50% (8,9). Among dogs at 52 
risk for developing proteinuric nephropathy, other than those living or having lived in endemic 53 
areas, there are also breeds that are genetically predisposed to proteinuric CKD (3,4,6,8). Early 54 
identification and treatment of proteinuria appears to be crucial in dogs, not only because of the 55 
high prevalence, but also as its management slows the progression of renal disease, risk of uremic 56 
crisis and renal-related death (1,3,4). Together with the treatment of the underlying disease, the 57 
major cornerstones of therapy in proteinuric CKD dogs are angiotensin converting enzyme 58 
inhibitors (ACEI), dietary intervention and omega-3 fatty acids which proved to slow the 59 
progression of renal disease, minimize clinical signs of uremia and, at least for the diet, to maintain 60 
either an optimal body weight (BW) and body condition score (1-3,6,9-14). However, in some dogs, 61 
anti-proteinuric therapy may not reduce proteinuria despite diets lower in protein compared to 62 
maintenance diets are administered concurrently (2-4,8-11,13,14). Furthermore, in proteinuric 63 
dogs renal diets may not adequately meet protein requirements, thus possibly leading to low BW, 64 
hypoalbuminemia and malnutrition. A previously published study on a spontaneous model of 65 
proteinuric nephropathy in dogs, showed that a low protein content diet (14% on dry matter basis), 66 
similar to the renal diets commonly recommended in dogs with kidney disease, caused a significant 67 
reduction in BW and plasma albumin concentration that were already noticeable at 4 weeks of 68 
administration (8). 69 
In humans with CKD, nutritional status is helpful to identify patients with increased risk of 70 
morbidity and mortality; a significant association, indeed, was observed between decreased baseline 71 
BW condition and subsequent risk of hospital admission (15-18). For these reasons, in 72 
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malnourished humans with CKD oral supplementation with amino acids (AA) or intradialytic AA 73 
administration have been proposed (15-19).  74 
In CKD dogs with severe proteinuria , either low BW and hypoalbuminemia are frequent and they 75 
can be associated with increased morbidity and risk of mortality (20). Indeed, albumin 76 
hypercatabolism and its down-regulated synthesis can contribute to glomerular disease-associated 77 
hypoalbuminemia, possibly leading to marked hypoalbuminemia in CKD dogs with sub-nephrotic 78 
range proteinuria thus worsening the prognosis (21). Based on this premise, it seems plausible that 79 
the amount of proteins needed should be individually-tailored in dogs, depending on the stage of 80 
CKD and the entity of proteinuria (8). As in humans, also in dogs AA supplementation may 81 
represent the easiest means to correct an insufficient daily intake of proteins. Thus, the aim of this 82 
retrospective case-control study was to investigate the impact of an oral AA supplementation during 83 
a short period of time on BW, serum concentrations of albumin, creatinine and urea, and on the 84 
urine protein-to-creatinine (UPC) ratio in proteinuric CKD dogs treated with enalapril and fed a 85 
commercial renal diet (RD). 86 
87 
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Materials and Methods 88 
Animals and inclusion criteria 89 
Medical records of proteinuric dogs in IRIS stages ≥2 (14) admitted in 2007 and 2008 at one of the 90 
authors’ institutions (AZ, PDI) were reviewed. All the data available regarding clinical history, 91 
physical examination, BW, complete blood count, serum biochemical profile, urinalysis, UPC ratio, 92 
indirect blood pressure measurements, abdominal ultrasonographic findings, ongoing treatments 93 
and follow-up examinations were collected. Dogs without stable renal function were excluded; 94 
stable renal function was defined by serum creatinine concentration that did not increase or decrease 95 
by 20% or more within one month from initial determination (10). Dogs were considered to be 96 
proteinuric if the UPC ratio was above 0.5 (IRIS substage P) (14) in two urine samples collected at 97 
one-month interval; dogs that did not fulfil this criterion were excluded. Furthermore, to be included 98 
in the study, dogs had to receive enalapril (Enacard®, Merial Italia spa, Milano, Italy) at 0.5 mg/kg 99 
(0.23 mg/lb), q 24 h, and a commercial renal diet (Hill’s Prescription Diet Canine k/d®, Hill’s Pet 100 
Nutrition Inc., Topeka, KS or Royal Canin Renal Canine®, Royal Canin SA, Aimargues, France); 101 
the amount of diet was according to the suggestions of the companies and corrections were not 102 
performed if dogs received or not AA supplementation. 103 
From each record, information was collected to identify dogs that received or not oral AA 104 
supplementation (IT IS pet, ACME srl, Cavriago (RE), Italy; formulation available in table 1). 105 
Among dogs on AA supplementation, only those taking the daily amount (mg) of AA arbitrarily 106 
calculated using the following formula, BW (kg) × [UPC ratio] × 20 = X (22), where X are the 107 
milligrams of amino acids to be administered daily were included. Based on the product indications, 108 
1 tablet provides approximately 675 mg of AA. Dogs that had received oral or intravenous AA 109 
supplementation within one month from time of admission were excluded. Finally, dogs were 110 
excluded if the diagnostic workup identified any inflammations or infections of the genitourinary 111 
tract (based on ultrasonography and urinalysis), a pre-renal cause of proteinuria (based on serum 112 
biochemistry), and if cardiac disease, neoplasia or endocrinopathies were diagnosed or suspected. 113 
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All dogs had been tested for leishmaniosis, ehrlichiosis and babesiosis, and were not included if an 114 
active form of infection was either identified or suspected. 115 
 116 
Additional treatments and follow-up 117 
As a standard of care at the authors’ institution, dogs classified as “severely hypertensive” (systolic 118 
arterial pressure ≥180 mm Hg) accordingly to the IRIS staging system (14) were treated with oral 119 
amlodipine at 0.1 to 0.5 mg/kg (0.05 to 0.23 mg/lb), q 24 h, in order to reduce systolic arterial 120 
pressure to <160 mm Hg (substage “normotensive” or “borderline hypertensive”). In addition, dogs 121 
with severe hypoalbuminemia received oral acetylsalicylic acid at 2.0 mg/kg (0.91 mg/lb), q 24 h, 122 
to prevent thrombosis. Based on the reference range of serum albumin (2.8 to 3.8 g/dL), dogs were 123 
considered hypoalbuminemic if the albumin concentration was ≤2.7 g/dL; severe hypoalbuminemia 124 
was arbitrarily defined as a value <2.0 g/dL. 125 
As stated above, dogs with proteinuric CKD were reassessed after one month to check if the renal 126 
disease was stable; all throughout the manuscript this time-point will be called baseline. After 127 
baseline, dogs were re-evaluated between 4-8 weeks. 128 
 129 
Blood sampling and assay 130 
During each examination, blood samples were collected in dogs fasted overnight, and serum was 131 
obtained within 30 minutes, stored at 4 °C (39 °F) and analyzed within 24 hours. Results from 132 
complete blood count and serum biochemical analysis, including albumin, total proteins, glucose, 133 
bilirubin, cholesterol, amylase, alanine transferase, alkaline phosphatase, urea nitrogen, creatinine, 134 
sodium, potassium, chloride and phosphate, were achieved with the same methods (BC-2800Vet, 135 
MINDRAY, Mindray Co. Ltd., Shenzhen, China; Cobas Mira, Roche Diagnostic AG, Basel, 136 
Switzerland) in all samples. 137 
 138 
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Urine collection and urinalysis 139 
An ultrasound-guided cystocentesis was performed in all dogs using a 5 mL syringe connected to a 140 
23-gauge needle. All urine samples were placed in 10 mL, sterile, evacuated collection tubes, and 141 
analyzed by the same operator. Urine samples were examined within 60 minutes from collection if 142 
samples were stored at room temperature (approximately 20 °C [676 °F]), or within 4 hours if 143 
stored at 4 to 8 °C (135 to 270 °F). Urine sediment was obtained by centrifugation (10 minutes at 144 
900 × g) of 5 mL of urine, followed by removal of 4.5 mL of supernatant, and resuspension of the 145 
remaining 0.5 mL of urine. A sample of 12 µL of the resuspended urine was microscopically 146 
assessed. The supernatant was transferred into separate tubes and stored at –20 °C (676 °F) to 147 
determine UPC ratio within 7 days. Red blood cells and white blood cells were expressed as mean 148 
number of cells/10 hpf (40 × magnification). Urine sediment with bacteriuria, and/or >5 red blood 149 
cells or white blood cells/hpf, was considered indicative of active inflammation and excluded from 150 
the UPC ratio evaluation (23). 151 
 152 
UPC ratio 153 
To calculate the UPC ratio, protein concentration (mg/dL) was measured with pyrogallol red, and 154 
creatinine (mg/dL) was measured using the Jaffé method on undiluted urine supernatant that was 155 
thawed before analysis. Analytes were measured in an automated spectrophotometer (Cobas Mira, 156 
Roche Diagnostic AG, Basel, Switzerland) in each case. 157 
 158 
Statistical analysis 159 
For data evaluation, BW, serum albumin, creatinine and urea concentrations, and the UPC ratio 160 
were retrieved from baseline and after 4-8 weeks in all dogs. Dogs that received the AA 161 
supplementation were included in the group A, those that did not receive the AA supplementation 162 
belonged to the group B (no placebo was provided). To verify whether population characteristics 163 
were similar in the two groups, baseline age, BW, serum albumin, creatinine and urea 164 
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concentrations, and UPC ratio were compared with unpaired t-test. Sex distribution, and frequency 165 
and severity of hypoalbuminemia were compared between groups with chi-squared test or Fisher’s 166 
exact test. 167 
To study the effect of AA supplementation, BW, serum albumin, creatinine and urea 168 
concentrations, and UPC ratio at baseline and after 4-8 weeks were compared within each group 169 
with paired t-test. Because severe hypoalbuminemia may be associated with morbidity and 170 
mortality in dogs (3,20,21), the effect of AA supplementation was also explored in the subset of 171 
cases with serum albumin concentration <2.0 g/dL by paired comparisons between baseline and 4-8 172 
weeks for the above parameters. Normality of all data sets was investigated with Kolmogorov-173 
Smirnov test and non-normally distributed variables were log-transformed to achieve Gaussian 174 
distribution prior to using parametric tests. Results are reported as mean ± standard deviation or as 175 
percentages. A P<0.05 was considered statistically significant. Statistical analysis was performed 176 
with commercial software (GraphPad Prism version 4.0, GraphPad Software Inc., La Jolla, CA). 177 
178 
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Results 179 
Baseline 180 
Forty-six proteinuric CKD dogs in IRIS stages 2, 3 or 4 were included; 29 of them received AA 181 
supplementation (group A), while the remaining 17 did not (group B). 182 
Age and BW of both groups are reported in table 2. In group A, 20 (69%) dogs were males (17 183 
intact and 3 castrated) and 9 (31%) were females (8 intact and 1 spayed). Regarding dog breeds, 7 184 
were Boxer, 2 of each were German Shepherd, Dogue de Bordeaux, Epagneul Breton or Italian 185 
Pointer, and one of each was Cocker Spaniel, Dachshund, Dalmatian, Doberman, Dogo Argentino, 186 
German Pointer, Golden Retriever, Jack Russel Terrier, Pitt Bull and Rottweiler; the remaining 4 187 
dogs were cross-breed. In group B, 11 (64.7%) dogs were intact males and 6 (35.3%) were females 188 
(5 intact and 1 spayed). Regarding dog breeds, 3 were Boxer, 2 were Great Dane, and one of each 189 
was American Staffordshire, Dalmatian, Dogo Argentino, Dogue de Bordeaux, English Setter, 190 
German Pointer, German Shepherd, Irish Wolfhound, Labrador and Pomeranian; the remaining 2 191 
dogs were cross-breed. Age, sex distribution and BW did not significantly differ between groups. 192 
Serum concentration of creatinine, urea and albumin, as well as UPC ratio of either group are 193 
reported in table 2. In group A, 18 (62.1%) dogs were in IRIS stage 2, 9 (31.0%) in IRIS stage 3 and 194 
2 (6.9%) were in IRIS stage 4. In group B, 7 (41.2%) dogs were in IRIS stage 2, 5 (29.4%) in IRIS 195 
stage 3 and 5 (29.4%) in IRIS stage 4. Serum concentration of creatinine was significantly lower in 196 
dogs in group A (P<0.05), whereas albumin and urea, and the UPC ratio did not significantly differ 197 
between groups. In group A, 20 (69.0%) dogs had low albumin concentration, 11 of which showing 198 
severe hypoalbuminemia; in group B, 11 (64.7%) dogs had low albumin concentration, 4 of which 199 
showing severe hypoalbuminemia. The frequency of dogs with hypoalbuminemia or severe 200 
hypoalbuminemia was not significantly different between groups A and B. 201 
 202 
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Weeks 4-8 203 
In group A at follow-up, BW increased in 16 (55.2%) dogs (range, from 0.5 to 4 kg), remained 204 
equal in 11 (37.9%) and decreased in 2 (6.9%); by arbitrarily considering BW as stable if increased 205 
or decreased by ≤2.5%, 14 (48.3%) of the 29 dogs had stable BW. The mean BW of dogs 206 
significantly increased by 6.2% (32 ± 15 kg; P<0.01), compared to baseline. BW was available for 207 
10 out of 17 dogs of group B and was increased in 1 (10.0%) dog, equal in 5 (50.0%) and decreased 208 
in 4 (40.0%); BW was stable in 5 (50.0%) of the 10 dogs. The mean value did not differ from 209 
baseline (26 ± 12 kg; P>0.05) (Figure 1).  210 
In group A, serum albumin concentration increased in 19 (65.5%) dogs, was equal in 2 (6.9%) and 211 
decreased in 8 (27.6%); by arbitrarily considering albumin as stable if increased or decreased by 212 
≤5%, 8 (27.5%) of the 29 dogs had stable albumin. The mean albumin concentration significantly 213 
increased by 0.2 g/dL (2.6 ± 0.7 g/dL; P<0.05), compared to baseline. None of the 19 dogs with 214 
higher than baseline albumin had concentrations above the reference range. In group B, albumin 215 
concentration increased in 8 (47.1%) dogs, was equal in 2 (11.8%) and decreased in 7 (41.2%); 216 
albumin was stable in 4 (23.5%) of the 17 dogs. The mean value did not differ from baseline (2.4 ± 217 
0.8 g/dL; P>0.05) (Figure 2). 218 
Serum concentration of creatinine in group A increased in 6 (20.7%) dogs and decreased in the 219 
remaining 23 (79.3%); by considering creatinine as stable if increased or decreased by ≤20% (10), 220 
13 (44.8%) of the 29 dogs had stable creatinine. In group B, creatinine concentration increased in 4 221 
(23.5%) dogs, was equal in 2 (11.8%) and decreased in 11 (64.7%); creatinine was stable in 6 222 
(35.3%) of the 17 dogs. In both groups, mean serum concentration of creatinine measured at 4-8 223 
weeks did not statistically differ from baseline (group A: 2.0 ± 2.0 mg/dL; group B: 3.4 ± 3.3 224 
mg/dL; P>0.05 for both). 225 
In group A, serum concentration of urea increased in 9 (31.0%) dogs, was equal in 1 (3.4%) and 226 
decreased in 19 (65.5%); by arbitrarily considering urea as stable if increased or decreased by 227 
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≤20%, 13 (44.8%) of the 29 dogs had stable urea. The mean urea concentration did not statistically 228 
differ from baseline (53 ± 76 mg/dL; P>0.05). In group B, urea concentration increased in 5 229 
(29.4%) dogs, was equal in 2 (11.8%) and decreased in 10 (58.8%); urea was stable in 6 (35.3%) of 230 
the 17 dogs. The mean urea concentration significantly decreased by 16 mg/dL (53 ± 35 mg/dL; 231 
P<0.05) (Figure 3). 232 
In group A, the UPC ratio increased in 9 (31.0%) dogs and decreased in 20 (69.0%); by arbitrarily 233 
considering UPC ratio as stable if increased or decreased by ≤20%, 7 (24.1%) of the 29 dogs had 234 
stable UPC ratio. The mean UPC ratio did not differ from baseline (3.9 ± 4.9; P>0.05). In group B, 235 
the UPC ratio increased in 2 (11.8%) dogs, was equal in 1 (5.9%) and decreased in 14 (82.3%); 236 
UPC ratio was stable in 5 (29.4%) of the 17 dogs. The mean UPC ratio significantly decreased by 237 
1.9 (2.4 ± 3.5; P<0.01) (Figure 4). 238 
The exact time of examination performed within the 4-8 weeks interval did not differ between 239 
groups (5.5 ±  1.0 weeks, both groups). 240 
 241 
Dogs with hypoalbuminemia 242 
In group A, AA supplementation increased serum albumin concentration at 4-8 weeks compared to 243 
baseline in all 11 dogs with severe hypoalbuminemia (serum albumin <2.0 g/dL). The mean 244 
albumin concentration significantly increased by 0.70 g/dL (P<0.001). None of these dogs had 245 
detectable subcutaneous edema or ascites, based on physical examination or abdominal 246 
ultrasonography, respectively. No significant differences were observed for BW, serum creatinine 247 
and urea concentrations, or the UPC ratio. At 4-8 weeks, the 9 dogs with hypoalbuminemia between 248 
2.0 and 2.7 g/dL had no significant change compared to baseline in BW, in serum albumin, 249 
creatinine and urea concentrations, or in UPC ratio. 250 
In group B, the 4 dogs with severe hypoalbuminemia at 4-8 weeks compared to baseline had 251 
albumin concentration that was decreased in 2 of them and was equal and increased in one of each 252 
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remaining. Due to the limited number of cases (4 dogs), statistical analyses were not performed for 253 
BW, serum albumin, creatinine and urea concentrations, or the UPC ratio. The 7 dogs with 254 
hypoalbuminemia (serum albumin between 2.0 and 2.7 g/dL) had no significant change in BW, 255 
serum albumin, creatinine and urea concentrations, or the UPC ratio at 4-8 weeks compared to 256 
baseline. 257 
258 
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Discussion 259 
A significant increase in serum albumin concentration compared to baseline was evident in 260 
proteinuric CKD dogs showing severe hypoalbuminemia (serum albumin <2.0 g/dL) when 261 
receiving the AA supplementation. Along with a beneficial effect on serum albumin level, 262 
supplementation with AA also increased dogs’ BW, albeit mildly. The effect on BW was evident in 263 
the whole group of proteinuric CKD dogs but not in those with severe hypoalbuminemia, possibly 264 
due to the worse nitrogen balance of the latter cases. On the other hand, even though 265 
supplementation with AA increased BW and serum albumin concentration in proteinuric CKD 266 
dogs, it delayed the decrease of proteinuria and prevented lowering of urea. 267 
Indeed, at follow-up, proteinuria and urea significantly decreased in dogs that did not receive AA 268 
while they did not differ in dogs supplemented with AA. It is therefore possible that in these dogs 269 
the reduced efficacy of the enalapril and commercial renal diet on either proteinuria or azotemia 270 
was a direct consequence of the positive nitrogen balance and increased protein synthesis induced 271 
by the AA supplementation. In fact, diets lower in protein compared to maintenance diets offer a 272 
chance to reduce the overall renal trafficking of protein, and if serum protein can be lowered then 273 
there is less risk of protein overload across the glomerular barrier, thus leading to less tubular 274 
protein reabsorption and inflammation (3). The amount of proteins in the diet has a well-known 275 
effect on the magnitude of proteinuria, and dogs fed with a diet lower in protein compared to 276 
maintenance diets have reduced proteinuria, which can in turn improve serum albumin 277 
concentration despite the reduction of albumin synthesis that can occur in CKD dogs (2,3,8). On the 278 
other hand, because a too strict restriction of protein intake can lead to loss of BW and decreased 279 
plasma albumin concentration, in proteinuric CKD dogs the protein amount administered daily with 280 
food should be tailored to the degree of proteinuria; in these patients, dietary therapy should 281 
minimize proteinuria and control plasma albumin concentration while not compromising the 282 
nutritional status (8,24). The correct amount of proteins might differ depending on the dog’s stage 283 
of renal disease and entity of proteinuria (8). The commercial renal diets currently available in dogs 284 
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have lower protein compared to maintenance diets and it is possible they do not meet the 285 
minimum requirements in case of severe proteinuria (thus leading to hypoalbuminemia and loss of 286 
BW). Meanwhile, the degree of proteinuria is strictly associated with survival and CKD progression 287 
in dogs (1,3,11). In light of these findings, it is the authors’ opinion that supplementation with AA 288 
should be carried out with caution in proteinuric CKD dogs, but it might be considered as an 289 
adjunctive therapy in severely hypoalbuminemic dogs in which the anti-proteinuric treatment has 290 
failed to control proteinuria and maintain plasma albumin concentration within normal limits. 291 
This study has some limitations including its retrospective nature and consequent lack of blinding. 292 
It is, therefore, possible that some of the effects would have been different if cases were randomly 293 
allocated to receive or not the AA supplementation and the 2 groups were more homogeneous. 294 
Indeed, serum concentration of creatinine at baseline was significantly higher in dogs that did not 295 
receive the AA supplementation. Then, it cannot be excluded that administering AA 296 
supplementation to dogs with higher creatinine concentration is associated with detrimental effects 297 
on renal function. In addition, follow-up time of all dogs included in the study was short. A longer 298 
follow-up period might have allowed depicting additional differences between the groups. 299 
Additionally, even though owners were instructed to feed their dogs just with one of the two renal 300 
diets available, sometimes they switched to the other. However, the effect of this potential bias was 301 
probably minor because both commercial renal diets were expected to be casually provided to dogs. 302 
Furthermore, studies comparing the effect of different diets in dogs with CKD have not been 303 
published yet but it is likely that the two commercial renal diets used for the present study provided 304 
similar beneficial effects. The IRIS simply suggests the use of a renal diet, without offering specific 305 
guidance on a particular brand on the market (14).  306 
Another limitation is represented by the fact that from medical records it was possible to retrieve 307 
BW but not the body or the muscle condition score of the dogs; the latter might have provided more 308 
information regarding the potential beneficial effect of AA supplementation . Furthermore, the 309 
increase of BW in dogs receiving supplementation of AA at follow-up might have been biased by 310 
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the concurrent presence of subcutaneous edema or abdominal effusion; however, none of the dogs 311 
with severe hypoalbuminemia in the present group developed any of the above. With regard to the 312 
same group of dogs, it is worth noting that at follow-up BW increased on average by only 6.2%, 313 
thus the beneficial effect of AA supplementation would be questionable. However, by considering 314 
the 16 dogs that had an increase of BW, the increase was from 0.5 to 4 kg, possibly suggesting a 315 
more relevant gain. 316 
Furthermore, the re-evaluation at 4-8 weeks may be considered a rather large interval, which might 317 
have affected the results. Although this hypothesis is conceivable, the potential bias was evenly 318 
distributed in the two groups, likely limiting the source of error. 319 
Another factor that might have affected the study results is that the AA provided with the 320 
supplementation were predominantly essential AA. Even though it has been demonstrated that 321 
people with CKD have a decrease of circulating essential AA relative to non-essential AA, (25,26) 322 
there are no data available regarding the AA blood profile of dogs with renal disease, particularly in 323 
those affected by spontaneous proteinuric CKD. Determining the AA profile of these dogs might 324 
prove useful to identify the specific AA that are needed to correct their imbalance.  325 
Finally, even though BW and serum albumin concentrations have been historically considered as 326 
insensitive and late indicators of malnutrition, in a previous study these values were considered 327 
clinically useful in assessing the adequacy of the nutritional status in dogs with renal proteinuria (8). 328 
Our results support the notion that serum albumin concentration represents a helpful indicator to 329 
plan dietary modification in proteinuric dogs affected by spontaneous CKD. 330 
In conclusion, proteinuric CKD dogs treated with enalapril and fed commercial renal diets that 331 
received supplementation with AA had improved BW and serum albumin concentration, while 332 
maintaining stable serum creatinine. However, administration of AA might delay the reduction of 333 
proteinuria and prevent lowering of urea. In light of these findings, the authors propose to address 334 
the AA supplementation to proteinuric dogs with severe hypoalbuminemia that are not adequately 335 
controlled with standard treatments consisting of renal diets and ACEI. Relying on serum albumin 336 
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was useful to identify the benefits of dietary changes in proteinuric dogs with CKD. Further clinical 337 
trials are expected to be valuable in order to evaluate the impact of different AA formulations on 338 
BW, hypoalbuminemia, and survival time of dogs affected by severe proteinuric CKD. 339 
 340 
Acknowledgements 341 
The authors are grateful to Dr. Barbara Contiero (University of Padova, Italy) for her statistical 342 
advise. 343 
344 
17 
 
References 345 
1) Jacob F, Polzin DJ, Osborne CA, Neaton JD, Kirk CA, Allen TA, Swanson LL. Evaluation 346 
of the association between initial proteinuria and morbidity rate or death in dogs with 347 
naturally occurring chronic renal failure. J Am Vet Med Assoc 2005;226:393-400.  348 
2) Littman MP. Protein-losing nephropathy in small animals. Vet Clin Small Anim 349 
2011;41:31-62. 350 
3) Harley L, Langston C. Proteinuria in dogs and cats. Can Vet J 2012;53:631-638. 351 
4) Nabity MB, Lees GE, Cianciolo R, Boggess MM, Steiner JM, Suchodolski JS. Urinary 352 
biomarkers of renal disease in dogs with X-linked hereditary nephropathy. J Vet Intern Med 353 
2012;26:282-293. 354 
5) Zini E, Bonfanti U, Zatelli A. Diagnostic relevance of qualitative proteinuria evaluated by 355 
use of sodium dodecyl sulfate-agarose gel electrophoresis and comparison with renal 356 
histologic findings in dogs. Am J Vet Res 2004;65:964-971. 357 
6) Grodecki KM, Gains MJ, Baumal R, Osmond DH, Cotter B, Valli VE, Jacobs RM. 358 
Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting 359 
enzyme (ACE) inhibitor. J Comp Pathol 1997;117:209-225. 360 
7) Matsuo S, Morita Y, Maruyama S, Manchang L, Yuzawa Y. Proteinuria and 361 
tubulointerstitial injury: the causative factors for the progression of renal diseases. Contrib 362 
Nephrol 2003;139:20-31. 363 
8) Burkholder WJ, Lees GE, LeBlanc AK, Slater MR, Bauer JE, Kashtan CE, et al. Diet 364 
Modulates Proteinuria in Heterozygous Female Dogs with X-Linked Hereditary 365 
Nephropathy. J Vet Intern Med 2004;18:165-175.  366 
9) Cortadellas O, Talavera J, Fernandez del Palacio MJ. Evaluation of the effects of a 367 
therapeutic renal diet to control proteinuria in proteinuric non-azotemic dogs treated with 368 
benazepril. J Vet Intern Med 2014;28(1):30-37. 369 
18 
 
10) Paltrinieri S, Solano-Gallego L, Fondati A, Lubas G, Gradoni L, Castagnaro M, et al. 370 
Guidelines for diagnosis and clinical classification of leishmaniasis in dogs. J Am Vet Med 371 
Assoc 2010;236:1184-1191. 372 
11) Lees GE, Brown SA, Elliott J, Grauer GE, Vaden SL. Assessment and management of 373 
proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal). J 374 
Vet Intern Med 2005;19:377-385. 375 
12) Jacob F, Polzin DJ, Osborne CA, et al. Clinical evaluation of dietary modification for 376 
treatment of spontaneous chronic renal failure in dogs. J Am Vet Med Assoc 377 
2002;220:1163-1170. 378 
13) IRIS Canine GN Study Group Standard Therapy Subgroup, Brown S, Elliott J, Francey 379 
T, Polzin D, Vaden S. Consensus recommendations for standard therapy of glomerular 380 
disease in dogs. J Vet Intern Med 2013;27 Suppl 1:S27-43. 381 
14) International Renal Interest Society [homepage on the Internet] c2016 International Renal 382 
Interest Sosiety (IRIS) Available from: http://www.iris-kidney.com/guidelines/index.html 383 
Last accessed June 11, 2016. 384 
15) Czekalski S, Hozejowski R. Intradialytic amono acids supplementation in hemodialysis 385 
patients with malnutrition: results of a multicenter cohort study. J Ren Nutr 2004;14:82-88. 386 
16) Cano NJM, Fouque D, Leverve XM. Application of branched-chain amino acids in human 387 
pathological states: renal failure. J Nutr 2006;136:299S-307S. 388 
17) Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, et al. Very low 389 
protein diet supplemented with ketoanalogs improves blood pressure control in chronic 390 
kidney disease. Kidney Int 2007;71:245-251. 391 
18) Lawson JA, Lazarus R, Kelly JJ. Prevalence and prognostic significance of malnutrition in 392 
chronic renal insufficiency. J Ren Nutr 2001;11:16-22. 393 
19 
 
19) Feiten SF, Draibe SA, Watanabe R, Duenhas MR, Baxmann AC, Nerbass FB, Cuppari L. 394 
Short term effects of a very-low protein diet supplemented with ketoacids in nondialyzed 395 
chronic kidney disease patients. Eur J Clin Nutr 2005;59:129-136.  396 
20) Klosterman ES, Moore GE, de Brito Galvao JF, DiBartola SP, Groman RP, Whittemore JC, 397 
et al. Comparison of signalment, clinicopathologic findings, histologic diagnosis, and 398 
prognosis in dogs with glomerular disease with or without nephrotic syndrome. J Vet Intern 399 
Med 2011;25:206-214. 400 
21) Parker VJ, Freeman LM. Association between body condition and survival in dogs with 401 
acquired chronic kidney disease. J Vet Intern Med 2011;25:1306-1311. 402 
22) Lulich JP, Osborne CA. Interpretation of urine protein-creatinine ratios in dogs with 403 
glomerular and nonglomerular disorders. Compend Cont Educ Pract Vet 1990;12:59-73. 404 
23) Beatrice L, Nizi F, Callegari D, Paltrinieri S, Zini E, D'Ippolito P, Zatelli A. Comparison of 405 
urine protein-to-creatinine ratio in urine samples collected by cystocentesis versus free catch 406 
in dogs. J Am Vet Med Assoc 2010;236:1221-1224.  407 
24) Parker VJ, Freeman LM. Focus on nutrition: nutritional management of protein-losing 408 
nephropathy in dogs. Compend Cont Educ Pract Vet 2012;34:E6. 409 
25) Flugel-Link RM, Jones MR, Kopple JD. Red cell and plasma amino acid concentrations in 410 
renal failure. JPEN Journal of parenteral and enteral nutrition 1983;7:450-456. 411 
26) Tizianello A, Deferrari G, Garibotto G, et al. Amino acid imbalance in patients with chronic 412 
renal failure. Contributions to nephrology 1989;75:185-193. 413 
414 
20 
 
Figure legends 415 
Fig. 1. Dot plot of BW in dogs in the group A and in the group B at baseline and after 4-8 weeks. 416 
After 4-8 weeks, BW significantly increased in the group A whereas did not change in the group B. 417 
 418 
Fig. 2. Dot plot of serum albumin concentration in dogs in the group A and in the group B at 419 
baseline and after 4-8 weeks. After 4-8 weeks, albumin significantly increased in the group A 420 
whereas did not change in the group B. 421 
 422 
Fig. 3. Dot plot of serum urea concentration in dogs in the group A and in the group B at baseline 423 
and after 4-8 weeks. After 4-8 weeks, urea significantly decreased in the group B whereas did not 424 
change in the group A. 425 
 426 
Fig. 4. Dot plot of UPC ratio in dogs in the group A and in the group B at baseline and after 4-8 427 
weeks. After 4-8 weeks, UPC ratio significantly decreased in the group B whereas did not change in 428 
the group A. 429 
 430 
431 
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Tables 432 
Table 1. Composition of the amino acid supplementation (100 grams). 433 
  Branched-chain aliphatic amino acids: 
    isoleucine, leucine, valine 
 
26 g 
  Aliphatic amino acids: 
    threonine, arginine, lysine 
 
24 g 
  Sulfur-containing amino acids: 
    cysteine, methionine 
 
7 g 
  Aromatic amino acids: 
    tyrosine, phenylalanine 
 
11 g 
  Heterocyclic amino acids: 
    tryptophan, histidine 
 
6 g 
  Carrier: 
    glucose 
    sucrose 
    pregelatinized rice 
 
10 g 
10 g 
6 g 
 434 
435 
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Table 2. Age, BW, serum concentration of creatinine, urea and albumin, as well as UPC ratio in 436 
dogs receiving AA supplementation (group A) and in dogs not receiving AA supplementation 437 
(group B), at baseline. 438 
 439 
 Group A 
(mean ±  SD) 
Group B 
(mean ±  SD) 
Age (years) 6 ± 3 6 ± 3 
BW (kg) 30 ± 14 28 ± 15 
Creatinine (mg/dL) 2.9 ± 1.3 4.6 ± 2.8 
Urea (mg/dL) 66 ± 30 69 ± 45 
Albumin (g/dL) 2.4 ± 0.7 2.4 ± 0.7 
UPC ratio 4.1 ± 4.5 4.3 ± 4.6 
 440 
SD, standard deviation; BW, body weight; UPC, urine protein to creatinine. 441 
 442 
